{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-015039","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.608557+00:00","generated_at":"2026-05-14T22:45:12.481791+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulse Biosciences expands ATM to allow insider purchases; major holder and CEO indicate likely buying","bullets":["Board authorized TD Cowen to sell shares to affiliates under existing ATM with up to $60M aggregate offering.","Robert Duggan (72% owner) and CEO Paul LaViolette indicate they are likely to purchase shares in near term.","No binding commitments or share counts; purchases would be at prevailing market bid or better."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015039","json":"https://secwatch.observer/filing/0001437749-26-015039.json","markdown":"https://secwatch.observer/filing/0001437749-26-015039.md","text":"https://secwatch.observer/filing/0001437749-26-015039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926015039/0001437749-26-015039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926015039/plse20260505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:45:12.481791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}